The Penny Stocks to Watch

SAN DIEGO, Sept. 13, 2011 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce that Chairman and CEO, Bob Stockman, is scheduled to make a presentation at the UBS Global Life Sciences Conference at 7:30 a.m. EDT on Tuesday, September 20, 2011. The conference is being held September 19-21, 2011 at the Grand Hyatt New York Hotel in New York City.

Mr. Stockman will present an overview of REVA and its proprietary ReZolve™ bioresorbable stent to institutional investors. A copy of the presentation materials will be available on the Company’s website at www.revamedical.com shortly after the presentation.

About REVA

REVA is a development stage medical device company incorporated in Delaware, USA, that is focused on the development and eventual commercialisation of its proprietary, bioresorbable stent products. REVA’s lead product, the ReZolve™ stent, combines REVA’s proprietary stent design with a proprietary polymer that is metabolised and cleared from the body. The ReZolve stent is designed to offer full x-ray visibility, clinically relevant sizing and a controlled and safe resorption rate. In addition, by early encapsulation of the stent in the artery tissue coupled with the loss of stent structure over time, the ReZolve stent may reduce the incidence of late forming blood clots, or thrombosis, a rare but serious problem associated with drug-eluting metal stents currently on the market. REVA is in the process of finalising the design of its ReZolve stent and will require regulatory approval before it can begin selling the ReZolve stent.

The REVA Medical, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8505

CONTACT: Investor and Media Enquiries:
         Cheryl Liberatore
         Director, Investor Relations and Marketing
         REVA Medical, Inc.
         +1 858-966-3045